https://www.pharmaceutical-technology.com/data-insights/tac-101-triumvira-immunologics-ovarian-cancer-likelihood-of-approval/
TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Ovarian Cancer.
ovarian cancertactriumviralikelihood
https://www.prnewswire.com/news-releases/triumvira-immunologics-strengthens-its-leadership-team-with-three-accomplished-life-sciences-executives-301881251.html
/PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the...
leadership teamtriumvirathreelife
https://www.pharmaceutical-technology.com/data-insights/tac-100-triumvira-immunologics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/
TAC-100 is under clinical development by Triumvira Immunologics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.
tactriumviraadenocarcinoma